HEALTH CARE:
BIOTECHNOLOGY & LIFE SCIENCES
SIC: BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
CRISPR Therapeutics AG is a bio-technology company. The Company researches, develops, and manufactures biological transformative gene-based medicines and other related products. CRISPR Therapeutics operates in Switzerland.
| Market Cap | 3.208 Billion | Shares Outstanding | 55.2 Million | Avg Volume | 984.991 Thousand |
| 1-Yr BETA vs S&P TR | 2.107 | Current Ratio | 16.81 | Quick Ratio | 16.81 |
| CRISPR Therapeutics AG Chart by YCharts | |
| Yahoo! Finance | finviz |
| SEC Web Site | SEC DEF 14A Filings |
Please sign in first
none
none
8 Thousand total shares from 1 transactions
| Insider Name | Type | Last Reported Shares Held | Last Reported Date | Filings in past year |
|---|---|---|---|---|
|
GREENE JOHN EVP & CHIEF FINANCIAL OFFICER |
|
27,502 | 2020-01-27 | 2 |
|
19,500,000 | 2020-01-24 | 1 | |
|
LUNDBERG SVEN ANTE PRESIDENT, CEO & PFO |
|
0 | 2020-01-03 | 0 |
|
643 | 2020-01-02 | 0 | |
|
12,455,252 | 2020-01-01 | 0 | |
|
HIGH KATHERINE A SEE REMARKS |
|
0 | 2019-12-17 | 2 |
|
KULKARNI SAMARTH CHIEF EXECUTIVE OFFICER |
|
172,320 | 2019-12-16 | 9 |
|
KASINGER JAMES R. GENERAL COUNSEL AND SECRETARY |
|
0 | 2019-12-03 | 3 |
|
HO TONY W EXECUTIVE VP, HEAD OF R&D |
|
0 | 2019-12-03 | 3 |
|
TOMSICEK MICHAEL JOHN CHIEF FINANCIAL OFFICER |
|
0 | 2019-12-03 | 2 |
|
KLEIN LAWRENCE OTTO CHIEF BUSINESS OFFICER |
|
0 | 2019-12-03 | 4 |
|
4,205,615 | 2019-11-19 | 3 | |
|
0 | 2019-11-19 | 4 | |
|
NOVAK RODGER PRESIDENT |
|
0 | 2019-11-19 | 5 |
|
2,982,855 | 2019-10-18 | 1 | |
|
0 | 2019-09-30 | 0 | |
|
0 | 2019-07-31 | 0 | |
|
0 | 2019-01-29 | 0 | |
|
|
6,824,685 | 2019-01-18 | 0 | |
|
5,380,940 | 2018-12-26 | 0 | |
|
0 | 2018-06-25 | 0 | |
|
VERSANT VENTURE CAPITAL V, L.P. VERSANT AFFILIATES FUND V, L.P. |
|
1,729,151 | 2018-04-24 | 0 |
|
VERSANT VENTURE CAPITAL IV, L.P. VERSANT VENTURE CAPITAL V, L.P. VERSANT AFFILIATES FUND V, L.P. |
|
4,004,248 | 2018-04-20 | 0 |
|
DYLAN-HYDE TYLER CHIEF LEGAL OFFICER |
|
25,204 | 2018-01-16 | 0 |
|
5,708,747 | 2018-01-05 | 0 | |
|
VERSANT VENTURE CAPITAL IV, L.P. VERSANT VENTURE CAPITAL V, L.P. VERSANT AFFILIATES FUND V, L.P. VERSANT OPHTHALMIC AFFILIATES I, L.P. |
|
4,606,242 | 2017-09-05 | 0 |
|
SUBRAMANIAN KALA SEE REMARKS |
|
0 | 2017-06-15 | 0 |
|
VERSANT VENTURE CAPITAL IV, L.P. VERSANT VENTURE CAPITAL V, L.P. VERSANT AFFILIATES FUND V, L.P. |
|
6,909,347 | 2016-10-24 | 0 |
|
VERSANT VENTURE CAPITAL IV, L.P. |
|
6,758,169 | 2016-10-24 | 0 |
| Reporting Owners | Transaction Date | Transaction Code | Shares | Share Price | Acquired or Disposed | Shares Owned Following Transaction | Combined shares owned after filing | Direct/Indirect Ownership | 10b-5 |
|---|---|---|---|---|---|---|---|---|---|
|
KULKARNI SAMARTH - Director - Officer CHIEF EXECUTIVE OFFICER |
2019-12-16 | M | 8,000 | d | 195,058 | 172,320.00 | direct | ||
|
KULKARNI SAMARTH - Director - Officer CHIEF EXECUTIVE OFFICER |
2019-12-16 | M | 8,000 | $1.81 | a | 172,320 | 172,320.00 | direct | |
| 2019-12-03 | A | 40,000 | a | 40,000 | 0.00 | direct | |||
| 2019-12-03 | A | 20,000 | a | 20,000 | 0.00 | direct | |||
| 2019-12-03 | A | 20,000 | a | 20,000 | 0.00 | direct | |||
| 2019-12-03 | A | 40,000 | a | 40,000 | 0.00 | direct | |||
|
KULKARNI SAMARTH - Director - Officer CHIEF EXECUTIVE OFFICER |
2019-12-03 | A | 120,000 | a | 120,000 | 0.00 | direct | ||
|
KULKARNI SAMARTH - Director - Officer CHIEF EXECUTIVE OFFICER |
2019-12-01 | F | 741 | $71.65 | d | 164,320 | 164,320.00 | direct |
